Yahoo Finance

In the first quarter, we originated new investments of approximately $261 million and received repayments of approximately $340 million that resulted in a slight decline in the comprehensive investment portfolio to $3.1 billion. SLR is one of a handful of private credit managers that have been in existence since before the great financial crisis. And we have the experience and strong track record of navigating a variety of market environments across credit cycles over a 20-year history. Cyclicality of the sponsor finance markets, which can be governed by the ebbs and flows of the markets, is a condition that is now not new to us as private credit investors. In fact, it is this condition that led us to diversify our investments away from strictly castle lending more than a decade ago via expansion to asset based lending in 2012.

Since then, SRLC has added several commercial finance teams to expand our investment strategies resulting in a more diverse private credit investment model. Our multi-strategy approach to private credit investing was on display in the first quarter as the very attractive lending friendly conditions that existed in 2023 in sponsor finance softened. Originations of $220 million from SLRC specialty finance investment verticals of asset-based lending, life sciences lending and equipment finance represented approximately 88% of total origination in the quarter. Said another way, only 20% of our first quarter originations were in sponsor finance, a sharp reversal of last year’s trend where sponsor finance originations comprised close to half of total originations in the first quarter of 2023.

While we expect the 2020 vintage for sponsor finance investments to be very strong for both us and the private credit industry more broadly, our flexible investment mandate allows us to shift to areas of less competition than which currently exists in sponsor finance market. Management teams and sponsors are increasingly exploring ways to raise new capital to support owning assets over longer timeframe to execute their business plan. This has resulted in an increasing opportunity for asset-based loans and liquidity solutions as middle-market companies grapple with both lower free cash flow and tighter working capital. ABL originations were more than $50 million in the quarter. Post quarter end, we have closed some attractive new ABL investments and have a strong pipeline of ABL investment opportunities.

We have also started to see some green shoots in the life science market following a period of muted transaction activity in 2023. In the first quarter, we originated $24 million via both new deals and DDTL draws based on borrowers hitting certain performance milestones. This related activity exceeded originations for the first half of 2023. Equity valuations for both private and public life science companies have begun to stabilize with credit investment opportunities continuing to improve. In equipment finance, the transition from banks to non-banks continues to rapidly evolve and our team’s deep industry expertise across a wide range of equipment solutions allows us to be a solution provider for both big and small companies. We continue to be pleased with the construction, quality and performance of our portfolio.

At quarter end, approximately 98% of our comprehensive investment portfolio was comprised of first lien senior secured loans. SLR’s longstanding focus on first lien loans has resulted in a portfolio which we believe is more conservatively positioned and better equipped to withstand persistent inflationary pressures and high interest rates than portfolios with second lien and broader cyclical exposure. As of March 31, our investments in non-accrual represented 0.8% and 0.6% of the investing portfolio on a cost and fair value basis respectively. We believe our low rate of non-accruals relative to the BDC sector is a result of our multi strategy approach or to specialty finance strategies which accounted for 75% of our comprehensive portfolio at March 31 enable us to be more selective in our sponsor finance investments.

In sponsor finance, the average EBITDA and revenue growth continues to be positive for our portfolio companies. Overall, they have successfully managed the transition to environment with higher cost of capital and inflation. The weighted average interest coverage on the sponsor finance loans has held steady at approximately 1.7x. Additionally and importantly, only 1.8% of our first quarter gross income is in the form of capitalized PIK income from cash flow borrowers resulting from amendments. We believe these healthy metrics are the result of our focus in sponsor finance on recession resilient industries, with high recurring free cash flow, such as healthcare, business and financial services. The credit quality of our specialty finance investments continue to be solid with attractive LTVs that have meaningful collateral support and borrowing base structures.

With the refinancing market open only to the best credits, sponsors are now focused on the remainder of their portfolios in this higher for longer rate environment. While we are optimistic that M&A will increase in the back half of the year, current activity remains centered on DTL draws and amended extends, which we are addressing very prudently. At March 31, including available credit capacity at SSLP and our specialty finance portfolio companies, we have approximately $800 million of available capital to deploy. From our seat today, we think SLRC is in a favorable position to take advantage of our either continued durable economic conditions or softened economy. I’ll turn the call now back over to Shiraz to take you through the first quarter financial highlights.

Shiraz Kajee: Thank you, Michael. SLR Investment Corp.’s net asset value at March 31, 2024 was $992 million or $18.19 per share compared to $987 million or $18.09 per share at December 31. At quarter end, SLRC’s on balance sheet investment portfolio has a market value of approximately $2.1 billion in 145 portfolio companies across 41 industries compared to a fair market value of $2.2 billion in 151 portfolio companies across 43 industries at December 31. At March 31, the company had approximately $1.2 billion of debt outstanding, with leverage of 1.16x net debt to equity. We expect our leverage ratio to remain in the middle of our target leverage range of 0.9x to 1.25x. SLRC’s funding profile is in a strong position to continue to weather the current interest rate environment.

Our existing $417 million of senior unsecured fixed notes have a weighted average annual interest rate of only 3.8%. And we expect to opportunistically access the investment grade debt market and are always in dialogue with investors in the fixed income community. Moving to the P&L for the 3 months ended March 31, gross investment income totaled $58.1 million versus $59.8 million for the 3 months ended December 31. Net expenses totaled $34.2 million for the 3 months ended March 31. This compares to $35.9 million for the prior quarter. Accordingly, the company’s net investment income for the 3 months ended March 31, 2024 totaled $23.9 million or $0.44 per average share, the same as the prior quarter. But overlying the company had net realized and unrealized gains for the first quarter totaling $4 million, versus the net realized and unrealized loss of $0.3 million for the fourth quarter of 2023.

As a result, the company had a net increase in net assets resulting from operations of $27.9 million for the 3 months ended March 31 compared to a net increase of $23.6 million, for the 3 months ended December 31, 2023. On May 8, the Board had declared a Q2 2024 quarterly distribution $0.41 per share payable on June 27, 2024 to holders of record as of June 13, 2024. With that, I’ll turn the call over to our Co-CEO Bruce Spohler.

Bruce Spohler: Thank you, Shiraz. We believe that SLRC’s commercial finance investment model provides us with the flexibility and capabilities to capitalize on the most attractive lending opportunities across our four private credit investment strategies. This diversity provides us with the flexibility to determine where we want to invest today and importantly, the ability to say no. We take a fundamental bottom up approach to our portfolio construction, based on the relative attractiveness or risk adjusted returns across our investment verticals. At quarter end, on a fair value basis, the comprehensive portfolio consisted of 3.1 billion of senior secured loans. to approximately 800 distinct borrowers. This was across 110 industries with 3.8 million as our average position.

Measured at fair value 99.3% of the portfolio consisted of senior secured loans, with 97.8% invested in first lien loans, including investments in the SSLP attributable to the company. And only 0.3% was invested in second lien cash flow loans. With the remaining portfolio invested in second lien asset based loans aggregating 1.2%. Our specialty finance investments account for approximately 75% of our comprehensive portfolio with the remaining 25% invested in senior secured cash flow loans to upper mid market sponsor backed companies. We believe that this defensive portfolio construction positions us well for potential economic weakness and provides a differentiated risk return profile for our shareholders, compared to cash flow only portfolios.

At quarter end, our weighted average asset level yield was 11.8%, up from 11.6% in the prior quarter. Our portfolio credit quality remained strong. At March 31st, the weighted average investment risk rating of our portfolio was just under 2 based on our 1 to 4 risk rating scale with 1 representing the least amount risk. Consistent with last quarter, over 97% of the portfolio is rated at 2 or higher. And 99.2% of the portfolio on a cost basis and 99.4% on fair value, we’re performing, with only two investments are non-accrual. Now let me turn to our four investment strategies. Sponsor finance or cash flow lending. And our sponsor finance business. We originate first lien senior secured loans to upper mid market companies in non-cyclical industries.

Such as healthcare, business services and financial services, which has helped us mitigate the impact from cyclical economic factors. At quarter end, our sponsored finance cash flow portfolio was approximately $750 million, which includes loans in the SSLP attributable to the company to invest it across 48 distinct borrowers. With approximately 99% of this cash flow portfolio invested in first lien loans, we believe our investments are well positioned to withstand liquidity pressures that borrowers may face in today’s environment. Additionally, we believe we have a defensively positioned portfolio. Our cash flow borrowers have a weighted average EBITDA of approximately $125 million, carry low LTV’s of approximately 40% and interest coverage of approximately 1.7x consistent with last quarter.

Our portfolio is comprised of businesses that perform essential services with either recurring or reoccurring revenues and have low capital intensity. Overall, our portfolio has exhibited solid credit metrics that have remained steady throughout this year. During the quarter, we originated $33 million of cash flow loans and experienced payments of $16 million. Our first quarter investments, all of which were first lien, have an average yield to expected maturity of 12.2% and leverage through our investment of 3.8x. Importantly, this leverage level is less than historical average for new issues. As Michael mentioned, sponsored finance deal flow continues to be muted, due to lower M&A volume. However, there are pockets in our defensive industries to invest on an attractive risk adjusted basis.

At quarter end, the weighted average cash flow yield was just under 12%. Now let me turn to our ABL segment. In the wake of the U.S. regional banking crisis last spring, the opportunities set for all of our ABL businesses has increased. As lending standards tightened at commercial banks, we saw an increase in ABL to flow. As a result, we were able to originate several attractive new investments, as new entrants with less experience have entered the space. We’ve remained committed to our high underwriting standards in which we focus on the quality of the underlying collateral. When determining acceptable loan to value lending ratios. The increase in our deal volume is enabling us to remain attractive – active, while being extremely selective.

At quarter end, our ABL portfolio totaled $930 million, representing 30% of our total portfolio and was invested in 166 different borrowers. The weighted average asset level yield was 15.7% compared to 14.5% in the prior quarter. For the first quarter, we had $53 million of new investments and repayments of $103 million across our ABL strategies. Now let me touch on equipment finance. At quarter end, this portfolio totaled $1 billion, representing a third of our total portfolio and was highly diversified across 550 borrowers. The credit profile of this portfolio continues to be solid, weighted average asset level yield was approximately 8%. During this quarter, we originated approximately $150 million of new investments and had repayments for approximately $143 million.

Our investment pipeline has expanded in conjunction with the disruption caused by last year’s regional bank failures. Finally, let me touch on life sciences. At quarter end, this portfolio totaled $338 million over 80% of our portfolio at par is invested in loans to borrowers that have over 12 months of cash runway. Additionally, all of our life science companies are generating revenue with at least one product in the commercialization stage. This significantly de-risks our underlying investment. Life science loans represented 11% of the portfolio and contributed over 22% of our gross investment income for the quarter. During the first quarter, the team funded $24 million of new investments and had repayments of $52 million, at quarter end the weighted average yield was approximately 13% on our life science loans and this excludes the addition of potential success fees and warrants.

While we expect valuations in the life sciences market to stabilize this year. We continue to see several new opportunities that we believe will meet our underwriting criteria. Given SLRC’s ability to allocate capital to the best risk-reward opportunities, we have the luxury of being highly selective in our capital deployment towards life sciences while still generating positive originations for the company overall. Lastly, I want to touch on the company’s investment in SSLP. SSLP was a strategic initiative which we put in place the end of 2022 following the merger with SLR Senior Investment Corp. This was done to rotate some lower yielding cash flow loans from SUNS portfolio. Six quarters after launching the initiative, we are pleased with the ramp of the portfolio and the income that has delivered thus far.

In the first quarter, SLRC earned $1.6 million from the SSLP program representing a 13.6% annualized yield. This compares to earnings of $1.1 million last quarter or an annualized yield of 10.3%. As of quarter end, investment commitments at the SSLP totaled $238 million and post quarter end we have invested an additional $6 million in the SSLP bringing our total commitments to $244 million. Now, let me turn the call back to Michael.

Michael Gross: Thank you, Bruce. In conclusion, we are pleased with the results achieved at SLRC in the first quarter 2024. The continued momentum we are seeing across the lending verticals and the credit quality and diversity of our investment portfolio. Asset quality remains top of mind for investors today, with tight risk premium price to cross risk assets. From our seat, we have started to see the dispersion in credit quality metrics within the private credit marketplace. And believe our history of conservatism and predominantly first lean investment portfolio with significant diversification has begun to differentiate our performance. As of March 31st, non-accrual investments represented 0.8% and 0.6% of the investment portfolio on a cost and fair value basis, respectively.

We believe our low rate of non-accruals is a result of our multi strategy approach which are specialty advanced strategies which accounted for 75% of our comprehensive portfolio at March 31st, enable us to be more selective in our sponsored finance business. Furthermore, only 1.8% of our gross investment income is in the form of capitalized pick on restructured cash flow loans, which we believe is also significantly below the peer group. Looking forward, we expect our origination opportunities to be driven by a combination of an increase in M&A activity, refinancings and regulatory forces impacting regional banks to the benefit of direct lenders such as SLRC. In addition, our specialty finance teams continue to seek tuck-in acquisition opportunities and have the resources and experience to acquire portfolios.

We continue to believe that a diversified portfolio approach across sponsor and commercial finance assets is most effective way to generate income and manage risk across economic cycle. Of the current market expectations are for rates to stay higher for longer, it is important to remember that specialty finance spreads and returns are not as volatile as cash flow sponsor finance investments. As a result, we would not expect yield contraction for specialty finance assets to the same extent as sponsor finance when base rates move lower. In closing, SLRC trades at a 10.5% dividend yield as of yesterday’s market close, which we believe presents an attractive investment for both income seeking and value investors and offers shareholders diversification benefits compared to sponsor finance only strategies.

Our investment advisors, alignment of interest with SLRC shareholders continues to be one of our hallmark principles. The SLR team owns over 8% of the company’s stock and includes having a significant percentage of their annual incentive compensation reinvested in SLRC stock. The team’s investment alongside fellow institutional and private wealth investors demonstrates our confidence in the company’s portfolio, stable funding and earnings outlook. We thank you all again for your time today as we know it’s an especially busy day for those that follow the list at BDC marketplace closely. Operator, will you please open up the line for questions.

Operator: [Operator Instructions] And we will take our first question from Erik Zwick with Hovde Group. Please go ahead.

See also

15 Best Places in Missouri for a Couple To Live on Only Social Security and

Kevin O’Leary’s Stock Portfolio: 10 Stock Picks for 2024.

To continue reading the Q&A session, please click here.